Expression of Enhancer of Zeste Homologue 2 (EZH2) and CD49f in breast cancer and its association with clinicopathological features
Overview
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Maulana Azad Medical College
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- The prevalence of EZH2 and CD49f in breast carcinoma
Overview
Brief Summary
Breast cancer is one of the most common tumor in women worldwide, with an estimated number of 2.3 million new cases globally. It is one of the leading causes of female mortality worldwide. To improve the prognosis and outcome of the disease, it is imperative to explore the comprehensive molecular mechanism underlying breast cancer.
This study is a cross sectional observation study on expression of Enhancer of zeste homolog 2 (EZH2) and CD49f in breast cancer and its association with clinicopathological features, that will be conducted in Department of Pathology, Maulana Azad Medical College, New Delhi, India. The primary outcome measures the prevalence of EZH2 and CD49f in breast carcinoma. The secondary outcome will be association of EZH2 and CD49f with clinicopathological features, Estrogen receptor, Progesterone receptor, Her2neu and Ki67 status
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18.00 Year(s) to 99.00 Year(s) (—)
- Sex
- Female
Inclusion Criteria
- •Newly diagnosed female patients of breast carcinoma whose biopsy specimens are received in Department of Pathology, MAMC.
Exclusion Criteria
- •Patients with prior neoadjuvant chemotherapy and/or radiation therapy.
Outcomes
Primary Outcomes
The prevalence of EZH2 and CD49f in breast carcinoma
Time Frame: Baseline
Secondary Outcomes
- 1) The association of EZH2 and CD49f with clinicopathological features of breast carcinoma like clinical stage, histological grade, tumor size and Tumor Infiltrating Lymphocytes(TILs)
Investigators
Dr Vandana Thakur
Maulana Azad Medical College